Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Trends in usage of the terms keratinocyte carcinoma and nonmelanoma skin cancer in the medical literature.

Beatson M, Misitzis A, Lew RA, Weinstock MA.

Br J Dermatol. 2019 Dec;181(6):1308-1309. doi: 10.1111/bjd.18213. Epub 2019 Aug 20. No abstract available.

PMID:
31175660
2.

A method to reduce imbalance for site-level randomized stepped wedge implementation trial designs.

Lew RA, Miller CJ, Kim B, Wu H, Stolzmann K, Bauer MS.

Implement Sci. 2019 May 3;14(1):46. doi: 10.1186/s13012-019-0893-3.

3.

Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply.

Weinstock MA, Lew RA, Shaw FM; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group.

JAMA Dermatol. 2018 Jul 1;154(7):851-852. doi: 10.1001/jamadermatol.2018.1230. No abstract available.

PMID:
29898230
4.

Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial.

Weinstock MA, Thwin SS, Siegel JA, Marcolivio K, Means AD, Leader NF, Shaw FM, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, Warshaw EM, Stricklin GP, Dellavalle RP, Sidhu-Malik N, Konnikov N, Werth VP, Keri JE, Robinson-Bostom L, Ringer RJ, Lew RA, Ferguson R, DiGiovanna JJ, Huang GD; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group.

JAMA Dermatol. 2018 Feb 1;154(2):167-174. doi: 10.1001/jamadermatol.2017.3631.

5.

Statistical considerations for stopping systemic lupus erythematosus clinical trials earlier.

Lew RA, Liang MH, Doros G.

Arthritis Res Ther. 2015 Dec 4;17:345. doi: 10.1186/s13075-015-0874-0. Review.

6.

Sponsor-Imposed Publication Restrictions Disclosed on ClinicalTrials.gov.

Stretton S, Lew RA, Ely JA, Snape MJ, Carey LC, Haley C, Woolley MJ, Woolley KL.

Account Res. 2016;23(2):67-78. doi: 10.1080/08989621.2015.1020375.

PMID:
26193425
7.

Diameter of dysplastic nevi is a more robust biomarker of increased melanoma risk than degree of histologic dysplasia: a case-control study.

Xiong MY, Rabkin MS, Piepkorn MW, Barnhill RL, Argenyi Z, Erickson L, Guitart J, Lowe L, Shea CR, Trotter MJ, Lew RA, Weinstock MA.

J Am Acad Dermatol. 2014 Dec;71(6):1257-1258.e4. doi: 10.1016/j.jaad.2014.07.030. Epub 2014 Nov 15. No abstract available.

PMID:
25454033
8.

Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.

Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA; CSP 555 Investigators.

J Nerv Ment Dis. 2014 Jan;202(1):13-7. doi: 10.1097/NMD.0000000000000069.

PMID:
24375206
9.

Therapies for active rheumatoid arthritis after methotrexate failure.

O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E; CSP 551 RACAT Investigators.

N Engl J Med. 2013 Jul 25;369(4):307-18. doi: 10.1056/NEJMoa1303006. Epub 2013 Jun 11.

10.

Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.

Weisbord SD, Gallagher M, Kaufman J, Cass A, Parikh CR, Chertow GM, Shunk KA, McCullough PA, Fine MJ, Mor MK, Lew RA, Huang GD, Conner TA, Brophy MT, Lee J, Soliva S, Palevsky PM.

Clin J Am Soc Nephrol. 2013 Sep;8(9):1618-31. doi: 10.2215/CJN.11161012. Epub 2013 May 9. Review.

11.

A comparison of statistical approaches for physician-randomized trials with survival outcomes.

Stedman MR, Lew RA, Losina E, Gagnon DR, Solomon DH, Brookhart MA.

Contemp Clin Trials. 2012 Jan;33(1):104-15. doi: 10.1016/j.cct.2011.08.008. Epub 2011 Sep 6.

12.

A SAS macro for a clustered logrank test.

Stedman MR, Gagnon DR, Lew RA, Jung SH, Losina E, Brookhart MA.

Comput Methods Programs Biomed. 2011 Nov;104(2):266-70. doi: 10.1016/j.cmpb.2011.02.001. Epub 2011 Apr 15.

13.

A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen.

Fiore LD, Brophy M, Ferguson RE, D'Avolio L, Hermos JA, Lew RA, Doros G, Conrad CH, O'Neil JA Jr, Sabin TP, Kaufman J, Swartz SL, Lawler E, Liang MH, Gaziano JM, Lavori PW.

Clin Trials. 2011 Apr;8(2):183-95. doi: 10.1177/1740774510395635.

14.

Lack of involvement of medical writers and the pharmaceutical industry in publications retracted for misconduct: a systematic, controlled, retrospective study.

Woolley KL, Lew RA, Stretton S, Ely JA, Bramich NJ, Keys JR, Monk JA, Woolley MJ.

Curr Med Res Opin. 2011 Jun;27(6):1175-82. doi: 10.1185/03007995.2011.573546. Epub 2011 Apr 7. Review.

PMID:
21473670
15.

Observational methods in comparative effectiveness research.

Concato J, Lawler EV, Lew RA, Gaziano JM, Aslan M, Huang GD.

Am J Med. 2010 Dec;123(12 Suppl 1):e16-23. doi: 10.1016/j.amjmed.2010.10.004. Review.

PMID:
21184862
16.

Phenylalanine-544 plays a key role in substrate and inhibitor binding by providing a hydrophobic packing point at the active site of insulin-regulated aminopeptidase.

Albiston AL, Pham V, Ye S, Ng L, Lew RA, Thompson PE, Holien JK, Morton CJ, Parker MW, Chai SY.

Mol Pharmacol. 2010 Oct;78(4):600-7. doi: 10.1124/mol.110.065458. Epub 2010 Jul 13.

PMID:
20628006
17.

β-Amino acid substitution to investigate the recognition of angiotensin II (AngII) by angiotensin converting enzyme 2 (ACE2).

Clayton D, Hanchapola I, Hausler N, Unabia S, Lew RA, Widdop RE, Smith AI, Perlmutter P, Aguilar MI.

J Mol Recognit. 2011 Mar-Apr;24(2):235-44. doi: 10.1002/jmr.1041.

PMID:
20549604
18.

Quenched fluorescent peptide substrates as tools for the discovery of novel cardiovascular disease biomarkers.

Smith AI, Warner FJ, Lew RA, Yarski M, McGrath B, Burrell LM.

Adv Exp Med Biol. 2009;611:419-22. No abstract available.

PMID:
19400248
19.

A SAS macro for a clustered permutation test.

Stedman MR, Gagnon DR, Lew RA, Solomon DH, Losina E, Alan Brookhart M.

Comput Methods Programs Biomed. 2009 Jul;95(1):89-94. doi: 10.1016/j.cmpb.2009.02.005. Epub 2009 Mar 24.

20.

The identification of a calmodulin-binding domain within the cytoplasmic tail of angiotensin-converting enzyme-2.

Lai ZW, Lew RA, Yarski MA, Mu FT, Andrews RK, Smith AI.

Endocrinology. 2009 May;150(5):2376-81. doi: 10.1210/en.2008-1274. Epub 2009 Jan 22.

PMID:
19164471
21.

Topical tretinoin therapy and all-cause mortality.

Weinstock MA, Bingham SF, Lew RA, Hall R, Eilers D, Kirsner R, Naylor M, Kalivas J, Cole G, Marcolivio K, Collins J, Digiovanna JJ, Vertrees JE; Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial Group.

Arch Dermatol. 2009 Jan;145(1):18-24. doi: 10.1001/archdermatol.2008.542.

PMID:
19153339
22.

An evaluation of statistical approaches for analyzing physician-randomized quality improvement interventions.

Stedman MR, Gagnon DR, Lew RA, Solomon DH, Brookhart MA.

Contemp Clin Trials. 2008 Sep;29(5):687-95. doi: 10.1016/j.cct.2008.04.003. Epub 2008 Apr 23.

PMID:
18571476
23.

Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase.

Ye S, Chai SY, Lew RA, Ascher DB, Morton CJ, Parker MW, Albiston AL.

Biochem Cell Biol. 2008 Jun;86(3):251-61. doi: 10.1139/o08-037.

PMID:
18523486
24.

Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor.

Lew RA, Warner FJ, Hanchapola I, Yarski MA, Ramchand J, Burrell LM, Smith AI.

Exp Physiol. 2008 May;93(5):685-93. doi: 10.1113/expphysiol.2007.040352. Epub 2008 Jan 25. Erratum in: Exp Physiol. 2015 Aug;100(8):988. Manohar, Jay [corrected to Ramchand, Jay].

25.

Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression.

Burchill L, Velkoska E, Dean RG, Lew RA, Smith AI, Levidiotis V, Burrell LM.

Exp Physiol. 2008 May;93(5):622-30. doi: 10.1113/expphysiol.2007.040386. Epub 2008 Jan 25.

26.

The association between statins and cancer incidence in a veterans population.

Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM.

J Natl Cancer Inst. 2008 Jan 16;100(2):134-9. doi: 10.1093/jnci/djm286. Epub 2008 Jan 8.

PMID:
18182618
27.

Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis.

Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, Smith AI, Burrell LM, Angus PW.

J Hepatol. 2007 Sep;47(3):387-95. Epub 2007 Apr 2.

PMID:
17532087
28.

Insulin-regulated aminopeptidase: analysis of peptide substrate and inhibitor binding to the catalytic domain.

Ye S, Chai SY, Lew RA, Albiston AL.

Biol Chem. 2007 Apr;388(4):399-403.

PMID:
17391061
29.

Medical hyperspectral imaging to facilitate residual tumor identification during surgery.

Panasyuk SV, Yang S, Faller DV, Ngo D, Lew RA, Freeman JE, Rogers AE.

Cancer Biol Ther. 2007 Mar;6(3):439-46. Epub 2007 Mar 16.

PMID:
17374984
30.

Development of a Tool to Assess the Team Leadership Skills of Medical Residents.

Orlander JD, Wipf JE, Lew RA.

Med Educ Online. 2006 Dec;11(1):4601. doi: 10.3402/meo.v11i.4601.

PMID:
28253776
31.

Protein Kinase C Regulates the Cell Surface Activity of Endothelin-Converting Enzyme-1.

Smith AI, Lew RA, Thomas WG, Tochon-Danguy N.

Int J Pept Res Ther. 2006 Sep;12(3):291-295. Epub 2006 May 19.

32.

Developmental expression of ACE2 in the SHR kidney: a role in hypertension?

Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, Smith AI, Thomas MC.

Kidney Int. 2006 Jul;70(1):34-41. Epub 2006 May 17.

33.

Lateralized cognitive dysfunction in patients with systemic lupus erythematosus.

Glanz BI, Schur PH, Lew RA, Khoshbin S.

Lupus. 2005;14(11):896-902.

PMID:
16335582
34.

Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2.

Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, Shaw T, Warner FJ, Zuilli A, Burrell LM, Angus PW.

Gut. 2005 Dec;54(12):1790-6. Epub 2005 Sep 15.

35.

Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells.

Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ.

J Biol Chem. 2005 Nov 25;280(47):39353-62. Epub 2005 Sep 15.

36.

Quenched fluorescent substrate-based peptidase assays.

Lew RA, Tochon-Danguy N, Hamilton CA, Stewart KM, Aguilar MI, Smith AI.

Methods Mol Biol. 2005;298:143-50.

PMID:
16044545
37.

Identification of angiotensin converting enzyme 2 in the rodent retina.

Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, Yarski M, Smith AI, Cooper ME.

Curr Eye Res. 2004 Dec;29(6):419-27.

PMID:
15764086
38.

The stability of lipidic analogues of GnRH in plasma and kidney preparations: the stereoselective release of the parent peptide.

Blanchfield JT, Lew RA, Smith AI, Toth I.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1609-12.

PMID:
15745807
39.

Myocardial infarction increases ACE2 expression in rat and humans.

Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, Johnston CI.

Eur Heart J. 2005 Feb;26(4):369-75; discussion 322-4. Epub 2005 Jan 25.

PMID:
15671045
40.

The zinc metallopeptidase family: new faces, new functions.

Lew RA.

Protein Pept Lett. 2004 Oct;11(5):407-14. Review. No abstract available.

PMID:
15544561
41.

The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis.

Douglas GC, O'Bryan MK, Hedger MP, Lee DK, Yarski MA, Smith AI, Lew RA.

Endocrinology. 2004 Oct;145(10):4703-11. Epub 2004 Jul 1.

PMID:
15231706
42.

Evaluation of methods for improving precision of blood pressure measurements in phase I clinical trials.

Terra SG, Blum RA, Wei GC, Lew RA, Digenio AG, Rajman I, Kazierad DJ.

J Clin Pharmacol. 2004 May;44(5):457-63.

PMID:
15102865
43.

HPLC in the analysis of peptide metabolism.

Lew RA.

Methods Mol Biol. 2004;251:275-90. No abstract available.

PMID:
14704452
44.

Regulators of the neuropeptide-degrading enzyme, EC 3.4.24.15 (thimet oligopeptidase), in cerebrospinal fluid.

Shrimpton CN, Wolfson AJ, Smith AI, Lew RA.

J Neurosci Res. 2003 Nov 1;74(3):474-8.

PMID:
14598324
45.

Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP).

Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL.

J Neurochem. 2003 Jul;86(2):344-50.

46.

Structure-activity study of LVV-hemorphin-7: angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase.

Lee J, Mustafa T, McDowall SG, Mendelsohn FA, Brennan M, Lew RA, Albiston AL, Chai SY.

J Pharmacol Exp Ther. 2003 Apr;305(1):205-11.

PMID:
12649370
47.

Endopeptidases 3.4.24.15 and 24.16 in endothelial cells: potential role in vasoactive peptide metabolism.

Norman MU, Reeve SB, Dive V, Smith AI, Lew RA.

Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H1978-84. Epub 2003 Feb 27.

48.

Metalloendopeptidases EC 3.4.24.15/16 regulate bradykinin activity in the cerebral microvasculature.

Norman MU, Lew RA, Smith AI, Hickey MJ.

Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H1942-8. Epub 2003 Feb 13.

49.

Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery.

Katz JN, Phillips CB, Baron JA, Fossel AH, Mahomed NN, Barrett J, Lingard EA, Harris WH, Poss R, Lew RA, Guadagnoli E, Wright EA, Losina E.

Arthritis Rheum. 2003 Feb;48(2):560-8.

50.

Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial.

Bischoff HA, Stähelin HB, Dick W, Akos R, Knecht M, Salis C, Nebiker M, Theiler R, Pfeifer M, Begerow B, Lew RA, Conzelmann M.

J Bone Miner Res. 2003 Feb;18(2):343-51.

Supplemental Content

Support Center